<DOC>
	<DOCNO>NCT00413452</DOCNO>
	<brief_summary>Purpose study evaluate immunogenicity overall safety etanercept SFP therapy administer weekly 24 week subject rheumatoid arthritis .</brief_summary>
	<brief_title>Etanercept SFP RA Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Men woman 18 year age old RA , define ACR criterion classification RA Na√Øve etanercept therapy Able selfinject investigational product designee Ethical Before studyspecific procedure , appropriate write informed consent must obtain Exclusion Criteria Receipt Corticosteroids &gt; 10 mg/day prednisone ( equivalent ) 14 day befor 1st dose investigational product Receipt MTX witin 30 day 1st dose investigational product Receipt investigational drug within 30 day 1st dose Receipt TNF inhibitor therapy within 90 day 1st dose Receipt cyclophosphamide within 6 mo 1st dose Current use nonsteroidal antiinflammatory drug ( NSAIDs ) greather maximum recommend dose product info sheet Current use insulin gnificant concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Enbrel</keyword>
	<keyword>Amgen</keyword>
</DOC>